Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0009402 (
colorectal cancer
)
53,228
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The expression of MMP-7 (pump-1) gene was examined in 10 cases of
colorectal cancer
by utilizing RT-PCR. In 9 out of 10 cases, MMP-7 mRNA was detected in cancerous tissue, whereas none was detected in adjacent normal colon tissue. However, this message was detected in only 1 out of 6 colon-cancer cell lines. In colonic mucosa from 3 patients with ulcerative colitis it was not detected. The expression of
MMP-2
(72-kDa type-IV collagenase) mRNA was also investigated in the same tissue samples, and was detected in all samples, including cancerous and non-cancerous tissue. Our data suggest that MMP-7 is expressed in a tumor-associated manner in colorectal cancers and may play a role in tumor progression.
...
PMID:Expression of MMP-7(PUMP-1) mRNA in human colorectal cancers. 851 52
Matrix metalloproteinases (MMP), such as 72 kDa type IV collagenase (
MMP-2
) and 92 kDa type IV collagenase (MMP-9), play an important role in tumor invasion and metastasis. Tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) are specific inhibitors of MMP. To evaluate the expression of TIMP-1, TIMP-2,
MMP-2
, and MMP-9 in human
colorectal cancer
, surgical specimens of primary
colorectal cancer
(66 cases) and liver metastases (10 cases) were examined by Northern and dot-blot hybridization. The levels of TIMP-1,
MMP-2
and MMP-9 mRNA were significantly higher in primary colorectal cancers than in their adjacent normal tissues, and those of the mRNAs for all four genes were significantly higher in liver metastases than in normal colorectal tissues. Higher levels of TIMP-1 mRNA were positively correlated with lymph node metastasis and the five-year survival, and higher levels of TIMP-1 and TIMP-2 mRNA were positively correlated with the Dukes classification. Our findings suggest that the expression of TIMP-1 and TIMP-2 is closely correlated with the progression of human
colorectal cancer
.
...
PMID:Enhanced expression of tissue inhibitors of metalloproteinases in human colorectal tumors. 889 69
The aim of this study was to investigate whether immunohistochemical staining patterns of tissue inhibitor of metalloproteinases TIMP-2 and matrix metalloproteinases
MMP-2
and MMP-9 can be predictors of tumour stage and survival time in
colorectal cancer
. Frozen tumour sections from 212 patients operated on between January 1987 and November 1990 were investigated. Three mouse monoclonal antibodies--T2-101 against TIMP-2, CA-4001 against
MMP-2
and GE-213 against MMP-9--were used. Positive expression of TIMP-2 (a) in basement membranes and (b) diffusely in stroma with (c) subglandular enhancement was found significantly (P < 0.01, P < 0.05, P < 0.05) more often in localized tumours than in tumours with regional or distant metastases. Neither pattern correlated with tumour differentiation. Patterns (a) and (c) correlated with longer survival time (P < 0.05); (b) reached near significance (P < 0.07). When the survival analyses were restricted to potentially cured patients, neither pattern could foretell death from cancer. Positive expression of
MMP-2
in tumour epithelium and of MMP-9 in tumour-infiltrating macrophages were both independent of tumour stage and were without correlation with survival time. A large number of MMP-9-positive macrophages correlated (P < 0.05) with poor tumour differentiation, whereas weak or absent epithelial
MMP-2
staining reached near significance (P < 0.08). Exploration of TIMP-2 expression is valuable for the discrimination between macroscopically localized and metastatic
colorectal cancer
, but it cannot predict which of the potentially cured patients are likely to have micrometastases.
MMP-2
and MMP-9 stainings are of minor value in staging and prognostic prediction.
...
PMID:Expression of tissue inhibitor of metalloproteinases TIMP-2 in human colorectal cancer--a predictor of tumour stage. 931 Feb 50
The expression of
MMP-2
and TIMP-2 was examined immunohistochemically in a total of 87
colorectal cancer
patients. The expression of
MMP-2
was in cancer cells: 76.5% (sm), 16.7% (pm), in cancer interstitial region: 92.2% (sm), 58.3% (pm), in transitional mucosal cells: 74.3% (sm), 17.1% (pm) and in transitional mucosal interstitial region: 80.0% (sm), 31.4% (pm). The expression of TIMP-2 was in cancer cells: 41.2% (sm), 16.7% (pm), in cancer interstitial region: 82.4% (sm), 69.4% (pm), in transitional mucosal cells: 57.1% (sm), 22.9% (pm) and in transitional mucosal interstitial region: 89.3% (sm), 57.1% (pm). These results suggest that the expression of
MMP-2
and TIMP-2 is induced in the sm cancer stage and is closely related to interactions in the cancer interstitial region for invasion and metastasis in patients with colorectal adenocarcinoma.
...
PMID:The expression of MMP-2 and TIMP-2 in patients with colorectal adenocarcinoma invaded to the submucosal and proper muscle layer. 946 52
This article describes the significance of mRNA expression of VEGF,
MMP-2
, MMP-9, and MT1-MMP in human
colorectal cancer
metastases, particularly hepatic metastases. The levels of gene expression were quantified by Northern blot hybridization in tumor and nontumor tissues obtained from 66 primary cases. Significantly higher levels of expression of VEGF mRNA were observed in patients with synchronous hepatic metastases (n = 15) and/or lymph node metastases than in those without. Patients with synchronous hepatic metastases had significantly higher levels of mRNA expression of all MMP genes than in those without, and no apparent correlation was seen between MMP mRNA expression and other clinicopathologic variables. Also in a study including 4 cases of metachronous hepatic metastases after surgery. VEGF, MMP-9, and MT1-MMP mRNA expression were significantly higher in patients with hepatic metastases than in those without, indicating that these are predictable markers for hepatic metastases. Immunohistochemical examination revealed that VEGF and MT1-MMP were localized mainly in cancer cells, whereas
MMP-2
and MMP-9 were distributed throughout stromal cells such as fibroblasts and leukocytes in tumor tissues.
...
PMID:[Implication of VEGF and MMPs in hepatic metastasis of human colon cancer]. 974 24
Breakdown of basement membrane (BM) is believed to be an essential step for tumor invasion and metastases. We have previously demonstrated that matrix metalloproteinase-9 (MMP-9), the 92 kDa collagenase expression correlates with metastases in human
colorectal cancer
(
CRC
). This study explores the relationship between the 72 and 92 kDa type IV collagenase (
MMP-2
and MMP-9) activities and pattern of type IV collagen expression during human colorectal tumorigenesis. Thirty-four
CRC
patients, including four synchronous adenomas and one synchronous liver metastases, were involved in this study. By immunohistochemical staining, type IV collagen expression was noted to be continuous in the BM of normal mucosa, adenoma and in two cases of carcinoma in situ. Limited or absent type IV collagen staining pattern was seen in 100 (19/19) and 23% (3/13) of
CRC
with and without metastases, respectively. By double immunostaining, MMP-9 protein expression was noted to localize within areas of limited type IV collagen staining. Similarly, type IV collagen staining was noted to be greatest in areas devoid of MMP-9 expression. Gelatin zymography detected both 92 and 72 kDa proenzyme forms in all
CRC
and normal mucosa extracts examined. The mean tumor/normal fold increases of the proMMP-2 and proMMP-9 enzyme forms were 1.6+/-0.1 (mean +/- SE) and 2.4+/-0.5 in adenomas, and 2.1+/-0.2 and 4.1+/-0.7 in
CRC
, respectively. The 62 and 82 kDa bands were present in 63 (12/19) and 74% (14/19) of
CRC
with metastases, compared with only 20 (3/15) and 33% (5/15) of
CRC
without metastases, respectively. These differences were significant (P = 0.045 and P = 0.030, respectively). Our results demonstrate that loss of BM type IV collagen along with elevations in
MMP-2
and MMP-9 expression, especially the activated forms, occur during colorectal tumorigenesis. Our data suggest that control of type IV collagenase activation may be beneficial in preventing human colorectal tumor progression.
...
PMID:Loss of basement membrane type IV collagen is associated with increased expression of metalloproteinases 2 and 9 (MMP-2 and MMP-9) during human colorectal tumorigenesis. 1033 90
The expression of
MMP-2
and TIMP-2 was examined immunohistochemically in a total of 36
colorectal cancer
patients with synchronous liver metastasis at the time of surgery, and the serum
MMP-2
and TIMP-2 levels were also measured in a total of 58
colorectal cancer
patients with/without liver metastasis following primary colorectal surgical resection for serological comparison. Although
MMP-2
exhibited a significant expression immunohistochemically in the primary
colorectal cancer
(p<0.05) and TIMP-2 in the synchronous liver metastasis (p<0.01), there was no relationship between the absence/presence of liver metastasis and serum
MMP-2
and TIMP-2 levels, respectively. These results suggest that it can be considered difficult to use serum
MMP-2
and TIMP-2 levels to predict the status of liver metastasis following primary resection in patients with colorectal adenocarcinoma.
...
PMID:The expression of MMP-2 and TIMP-2 in patients with primary colorectal adenocarcinoma: correlation with liver metastasis. 1042 88
Numerous studies have demonstrated the persistent localization of matrix metalloproteinase (MMP) expression to the interface between invading human
colorectal cancer
(
CRC
) cells and surrounding stroma supporting a role for MMPs in
CRC
invasion and metastasis. The present study sought to determine whether
CRC
cells of varying metastatic potential would have differential effects on host MMP release. Subcutaneous
CRC
tumors were generated in BALB/c nude mice using three
CRC
cell lines: SW480, SW620, and the highly metastatic SW620S5 clone. Representative samples from the subcutaneous
CRC
were then orthotopically implanted on the cecum of recipient nude mice. Subcutaneous and cecal tumors were analyzed for MMP expression via zymography, western blot, and RT-PCR. In vitro, none of the three cell lines expressed
MMP-2
nor MMP-9. In contradistinction, the subcutaneous tumors expressed limited amounts of
MMP-2
and MMP-9 while the cecal tumors expressed significant amounts of
MMP-2
and MMP-9 as well as other smaller members of the MMP family. MMP-9 mRNA and protein was confirmed as host in origin by RT-PCR with mouse specific primers and a mouse MMP-9 molecular weight of 105 kDa as determined by zymography and western blot analysis. In situ hybridization also localized the mRNA for MMP-9 to the host stromal cells. In conclusion,
CRC
cells appear incapable of producing
MMP-2
and MMP-9 in vitro but are capable of up-regulating host MMP production in vivo. Enhanced host MMP-9 production in metastatic
CRC
cell-derived subcutaneous and cecal tumors suggests that metastatic colon cells may acquire the expression of important MMP regulating factor(s) in vivo.
...
PMID:Metastatic and non-metastatic colorectal cancer (CRC) cells induce host metalloproteinase production in vivo. 1054 21
The matrix metalloproteinases,
MMP-2
and MMP-9, are capable of degrading components of the basement membrane, a vital barrier breached during the progression of
colorectal cancer
. The regulation of
MMP-2
activation and subsequent targets is vital to understanding the metastatic process.
MMP-2
was not expressed by
colorectal cancer
cells (C170 and C170HM(2)) in vitro but by stromal fibroblasts (46BR.1GI). There was induction of this MMP upon transwell co-cultivation of the colon cancer cells with the fibroblasts but in vivo growth did not lead to a similar increase in the metastatic tumour cells (C170HM(2)),
MMP-2
again being attributed to the stromal cells.
MMP-2
mRNA was overexpressed in human colorectal tumours compared to normal colorectal tissue, which correlated with Dukes' stage and immunolocalized to the stromal compartment of the tumour tissue. The active form of the
MMP-2
enzyme was also present in the colorectal tumour tissue (7/8) but essentially absent in all normal colon samples examined (1/8).
MMP-2
activation was not related to an increase in MT-1-MMP mRNA or a decrease in the specific inhibitor TIMP-2 in human tissue. There was however an increase in
MMP-2
/TIMP-2 ratio in tumour compared to normal. MMP-9, a target of active
MMP-2
, was present in the metastatic cell line but expression was down-regulated in the tumour cells in vivo, gelatin analysis revealed that MMP-9 was almost entirely attributable to the murine host, confirmed by PCR. There was no increase in mRNA for MMP-9 or its specific inhibitor TIMP-1 in colorectal tumour tissue compared to normal, MMP-9 protein localized to the inflammatory infiltrate. Fibroblast cells may provide malignant epithelial cells with a ready source of enzyme which is crucial to the metastatic process.
...
PMID:Spectrum of matrix metalloproteinase expression in primary and metastatic colon cancer: relationship to the tissue inhibitors of metalloproteinases and membrane type-1-matrix metalloproteinase. 1140 21
Colorectal cancer
is one of the most common malignant tumors and entails a relatively poor prognosis. Clinical outcome depends on the extent of local and metastatic tumor spread. Results of in vivo and in vitro studies suggest that the balance between matrix metalloproteinases (MMPs) and their inhibitors (tissue inhibitors of metalloproteinases TIMPs) is altered in neoplasia, contributing to the invasive and metastatic properties of malignant tumors. We quantified tissue concentrations of
MMP-2
and TIMP-2 in 65 malignant colorectal lesions and corresponding normal mucosa by enzyme-linked immunosorbent assay, western blotting, and in situ hybridization. In situ hybridization and western blot analyses demonstrated a clear increase in both stromal expression of
MMP-2
transcripts and protein in primary carcinomas. The protein concentration of
MMP-2
was higher in all tumor stages, except stage I tumors, than in normal mucosa and adenomas.
MMP-2
concentrations were not related to tumor differentiation or to colonic versus rectal location. Surprisingly, the
MMP-2
concentration was not increased in metastases. Interestingly, tissue concentrations and epithelial mRNA expression of TIMP-2 decreased significantly in primary
colorectal cancer
(UICC stages III and IV) but increased in metastases. Therefore an increased ratio of
MMP-2
to TIMP-2 is strongly associated with advanced tumor stages, but a decreased ratio was observed in metastases. These findings suggest that the
MMP-2
:TIMP-2 ratio may prove useful as a marker of local invasion but not of metastasis in
colorectal cancer
.
...
PMID:Increased matrix metalloproteinase 2 concentration and transcript expression in advanced colorectal carcinomas. 1145 86
1
2
3
4
5
6
7
8
9
10
Next >>